share_log

Eli Lilly and Co | DEF 14A: Definitive information statements

Eli Lilly and Co | DEF 14A: Definitive information statements

禮來 | DEF 14A:股東委託書決議
SEC announcement ·  03/22 16:28
Moomoo AI 已提取核心訊息
Eli Lilly and Co (Lilly) has announced a series of significant achievements and strategic initiatives in its 2023 annual report, reflecting the company's commitment to advancing healthcare and delivering value to shareholders. The company received regulatory approvals for Omvoh, Jaypirca, and Zepbound, which address ulcerative colitis, MCL/CCL, and obesity, respectively. Lilly also reported positive results from the Trailblazer-ALZ 2 study, indicating a slowdown in Alzheimer's disease progression. The company's strong financial performance included robust shareholder returns through December 31, 2023. Lilly's community investment included over $4 billion in medicine donations in the US and $68 million in global humanitarian aid. The company's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030, with an estimated reach...Show More
Eli Lilly and Co (Lilly) has announced a series of significant achievements and strategic initiatives in its 2023 annual report, reflecting the company's commitment to advancing healthcare and delivering value to shareholders. The company received regulatory approvals for Omvoh, Jaypirca, and Zepbound, which address ulcerative colitis, MCL/CCL, and obesity, respectively. Lilly also reported positive results from the Trailblazer-ALZ 2 study, indicating a slowdown in Alzheimer's disease progression. The company's strong financial performance included robust shareholder returns through December 31, 2023. Lilly's community investment included over $4 billion in medicine donations in the US and $68 million in global humanitarian aid. The company's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030, with an estimated reach of 15 million patients by the time of the report. Lilly engaged with investors on topics such as drug pricing, global product access, and enterprise risks. The board proposed management initiatives for the 2024 annual meeting to eliminate the classified board structure and supermajority voting requirements in the articles of incorporation. The company's commitment to making life better for people worldwide was reiterated, with the Annual Meeting set to welcome shareholders virtually on May 6, 2024.
禮來公司(Lilly)在其2023年年度報告中宣佈了一系列重大成就和戰略舉措,反映了公司對推進醫療保健和爲股東創造價值的承諾。該公司分別針對潰瘍性結腸炎、MCL/CCL和肥胖症的Omvoh、Jaypirca和Zepbound獲得了監管部門的批准。禮來公司還報告了Trailblazer-ALZ 2研究的積極結果,表明阿爾茨海默氏病進展放緩。該公司強勁的財務業績包括截至2023年12月31日的強勁股東回報。禮來公司的社區投資包括在美國的超過40億美元的藥品捐贈和6800萬美元的全球人道主義援助。該公司的30x30目標旨在到2030年在資源有限的環境中改善3000萬人的醫療保健,截至報告發布時,估計...展開全部
禮來公司(Lilly)在其2023年年度報告中宣佈了一系列重大成就和戰略舉措,反映了公司對推進醫療保健和爲股東創造價值的承諾。該公司分別針對潰瘍性結腸炎、MCL/CCL和肥胖症的Omvoh、Jaypirca和Zepbound獲得了監管部門的批准。禮來公司還報告了Trailblazer-ALZ 2研究的積極結果,表明阿爾茨海默氏病進展放緩。該公司強勁的財務業績包括截至2023年12月31日的強勁股東回報。禮來公司的社區投資包括在美國的超過40億美元的藥品捐贈和6800萬美元的全球人道主義援助。該公司的30x30目標旨在到2030年在資源有限的環境中改善3000萬人的醫療保健,截至報告發布時,估計將覆蓋1500萬名患者。禮來就藥品定價、全球產品准入和企業風險等話題與投資者進行了接觸。董事會爲2024年年會提出了管理舉措,以取消公司章程中的機密董事會結構和絕大多數投票要求。公司重申了改善全球人民生活的承諾,年會定於2024年5月6日以虛擬方式歡迎股東。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息